An observational study in Myopia and Myopic Macular Degeneration, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Completed at 1 site in China. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Observational
Myopia has become a global public health issue. Myopia affects the psychological health of children and adolescents and poses a financial burden. Therefore, early detection and prediction of children at a high risk of myopia development and progression are critical for precise and effective interventions. In this study, we developed a deep learning system DeepMyopia, based on fundus images with the following objectives: 1) to predict myopia onset and progression; 2) To detect myopic macular degeneration for AI-assisted diagnosis; 3) To predict the development of myopic macular degeneration; 4) evaluate its cost-effectiveness.
Myopia has become a global public health issue. Myopia affects the psychological health of children and adolescents and poses a financial burden. Furthermore, as myopia progresses it increases the risk of ocular complications such as myopic macular degeneration, leading to irreversible visual impairment or even blindness. According to the World Health Organization , more than 1 billion people worldwide are living with vision impairment caused by myopia, hyperopia, and other problems due to late detection. Therefore, early detection and prediction of children at a high risk of myopia development and progression are critical for precise and effective interventions.
In this study, we developed a deep learning system DeepMyopia, based on fundus images with the following objectives: 1) to predict myopia onset and progression; 2) To detect myopic macular degeneration for AI-assisted diagnosis; 3) To predict the development of myopic macular degeneration; 4) evaluate its cost-effectiveness.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's enrollment of 30,526 is above the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 64 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The SCALE, a prospective, school-based study, includes all children aged 4 to 14 years in Shanghai.
The SCALE-HM, a population-based, prospective, examiner-masked study, includes children and adolescents aged between 4 and 18 years with high myopia.
The STORM trial, a school-based, prospective, examiner-masked, cluster-randomized trial, includes children aged 6 to 9 years.
The SMS study is a school-based cross-sectional survey from Shanghai, including kindergarten and primary school students in Year 1 and 2.
The Beijing Children Eye study included children who came to the outpatient clinic of Beijing Friendship Hospital.
The JFFT study contains cross-sectional data from Shanghai, Yunnan, Inner Mongolia, Xinjiang and Guangzhou.
The Hong Kong Children Eye Study is a population-based cohort study of eye conditions in children aged 6-8 years.
Exclusion Criteria:
The training dataset was comprised of data from a school-based, prospective cohort (the Shanghai Time Outside to Reduce Myopia \[STORM\] trial) and data from another population-based, prospective study, the High Myopia Registration Study (SCALE-HM), with annual follow-up. Participants of the two studies were divided into a training set (70%), a tuning set (10%), and an internal test set (20%), which were not duplicated by each other at the participant level.
Diagnostic Test: A deep learning-based myopia and myopic maculopathy detection and prediction system
The internal validation dataset was comprised of data from a school-based, prospective cohort (the Shanghai Time Outside to Reduce Myopia \[STORM\] trial) and data from another population-based, prospective study, the High Myopia Registration Study (SCALE-HM), with annual follow-up. Participants of the two studies were divided into a training set (70%), a tuning set (10%), and an internal test set (20%), which were not duplicated by each other at the participant level.
Diagnostic Test: A deep learning-based myopia and myopic maculopathy detection and prediction system
To test the extrapolation capabilities of the deep learning sysyem, two independent datasets, the Joint Five-site Fundus Test (JFFT) and the Hong Kong Children Eye Study (HKCES), were applied as external test sets. The JFFT study, a multi-site dataset, contains cross-sectional data from Shanghai, Yunnan, Inner Mongolia, Xinjiang and Guangzhou. HKCES, a population-based cohort study of eye conditions in children aged 6-8 years.
Diagnostic Test: A deep learning-based myopia and myopic maculopathy detection and prediction system
This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
myopia staging detection possibility score
output of myopia staging task
Time frame: immediately after inputting the data
myopic maculopathy detection possibility score
output of myopic maculopathy detection task
Time frame: immediately after inputting the data
predicted spherical equivalent
output of assessing spherical equivalent task
Time frame: immediately after inputting the data
predicted future annual spherical equivalent
output of predicting future spherical equivalent task
Time frame: immediately after inputting the data
risk score of myopia and myopic maculopathy progression
output of the progression of myopia and myopic maculopathy predicion task
Time frame: immediately after inputting the data
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Eye Disease Prevention and Treatment Center